Mark Cuban has no doubt he can disrupt health care

Taking stock of the drug industry, from the lab to the medicine chest

October 16, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Screen Capture via STAT STAT+ | A former top Trump health official lays out how the GOP should revisit fights over drug pricing and the ACA Republicans will need to rework Biden's drug pricing law and let the expanded ACA subsidies end, should Trump take office. By Sarah Owermohle Opinion: Mark Cuban has no doubt he can disrupt health care "This is literally the easiest industry to interrupt, to disintermediate, that I've ever been involved with," he said on the "First Opinion Podcast." By Torie Bosch STAT+ | Opinion: Bayer Pharmaceuticals COO: The 2024 campaign is full of good intentions — and bad policy Bayer's Sebastian Guth is focused on the election's implications for PBM reform, 340B, price setting, and IP protections. By Sebastian Guth Illustration: Christine Kao/STAT; Photos: Getty Images STAT+ | Q&A: FDA chief on why our hearts are less healthy, how obesity drugs impress him, and what worries him A Q&A with the FDA commissioner and cardiologist about the nation's backsliding on cardiovascular health and what to do about it. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser